Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Africa News Online.
Press releases published on June 24, 2025
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
GlobeNewswire
·
June 24, 2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 24, 2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewswire
·
June 24, 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight
GlobeNewswire
·
June 24, 2025
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss. No treatment-related serious adverse events were reported. …
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
GlobeNewswire
·
June 24, 2025
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and …
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
GlobeNewswire
·
June 24, 2025
RECORDATI ANNOUNCES EXCLUSIVE LICENSING …
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
GlobeNewswire
·
June 24, 2025
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing …
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
GlobeNewswire
·
June 24, 2025
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach …
Erdene Releases 2025 Shareholder Letter
GlobeNewswire
·
June 24, 2025
HALIFAX, Nova Scotia, June 24, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to publish its 2025 Letter to Shareholders authored by President and CEO, Peter Akerley. To read the …
AAS Miner will become the top free cloud mining platform for passive income from mining BTC, ETH and other cryptocurrencies in 2025
GlobeNewswire
·
June 24, 2025
Hale, Altrincham, United Kingdom, June 24, 2025 (GLOBE NEWSWIRE) -- With the booming digital currency market, mining has become a new outlet for wealth pursued by many investors. However, traditional mining is daunting due to problems such as expensive …
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
GlobeNewswire
·
June 24, 2025
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a …